Acetyl-L-Carnitine (ALCAR)

ALCAR exerts neuroprotective and cognitive effects through several interconnected mechanisms. Upon crossing the blood-brain barrier, ALCAR donates its acetyl group to coenzyme A, producing acetyl-CoA, which serves as a substrate for both the Krebs cycle (energy production) and the synthesis of acetylcholine (a critical neurotransmitter for learning, memory, and attention). This dual function simultaneously enhances cerebral energy metabolism and cholinergic neurotransmission. ALCAR also modulates nerve growth factor (NGF) receptor expression and promotes neuronal survival and regeneration, which is relevant to peripheral neuropathy and neurodegenerative conditions. It increases brain levels of dopamine and serotonin in preclinical studies, contributing to its antidepressant effects. ALCAR enhances mitochondrial membrane potential and function, supporting neuronal bioenergetics and protecting against age-related mitochondrial decline. It reduces oxidative stress in neural tissue through upregulation of antioxidant enzymes including heme oxygenase-1 (HO-1) and by maintaining glutathione levels. Additionally, ALCAR modulates synaptic plasticity by influencing AMPA and NMDA receptor expression, mechanisms relevant to learning and memory consolidation.

ALCAR has been studied primarily for cognitive decline, depression in older adults, and neuropathy. Wang et al. (2014) conducted a systematic review of ALCAR in depression, analyzing 12 randomized controlled trials and concluding that ALCAR demonstrated antidepressant efficacy comparable to established antidepressants, with significantly fewer side effects, particularly in older populations. Pettegrew et al. (2000) provided a foundational review of ALCAR's physical-chemical, metabolic, and therapeutic properties, documenting improvements in brain energy metabolism and cognitive function in Alzheimer's disease patients. Malaguarnera et al. (2008) demonstrated in a randomized, double-blind trial that 2 g/day of ALCAR for 180 days significantly reduced physical and mental fatigue in elderly patients aged 70–92 years while improving cognitive function and physical activity. For peripheral neuropathy, a meta-analysis by Li et al. (2015) across five randomized trials found that ALCAR (1500–3000 mg/day) significantly improved pain scores and nerve conduction parameters in diabetic peripheral neuropathy. Gavrilova et al. (2011) studied ALCAR in early-stage Alzheimer's and vascular dementia, finding improvement in attention, memory, and verbal fluency. ALCAR is approved as a pharmaceutical in several European countries for cognitive decline and neuropathy.

Acetyl-L-carnitine

ALCAR has moderate oral bioavailability (approximately 10–20%) but crosses the blood-brain barrier significantly more efficiently than L-carnitine due to its acetylated structure. Peak plasma levels are reached within 1–3 hours of oral ingestion. Taking ALCAR on an empty stomach may enhance absorption. The acetyl group is cleaved during absorption, but re-acetylation occurs in tissues.

• Red meat (beef, lamb — contain small amounts of ALCAR)
• Pork
• Chicken and poultry
• Fish
• Dairy products (whole milk, cheese)
• Asparagus (trace amounts)